Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22141963 | 0.95 | CCR2 (0.35) | HTR2ACCR2CCR1CCR5CXCR4 | |
| SCHEMBL22023694 | 0.95 | HTR2A (0.33) | HTR2ACCR2CCR1CCR5CXCR4 | |
| SCHEMBL22024142 | 0.95 | HTR2A (0.33) | HTR2A | |
| SCHEMBL22142074 | 0.95 | CCR2 (0.35) | HTR2ACCR2CCR1CCR5CXCR4 | |
| SCHEMBL24736818 | 0.93 | CCR2 (0.34) | HTR2ACCR2CCR1CCR5CXCR4 | |
| SCHEMBL26317203 | 0.93 | CCR2 (0.34) | HTR2ACCR2CCR1CCR5CXCR4 | |
| SCHEMBL21191726 | 0.91 | HTR2A (0.34) | HTR2A | |
| SCHEMBL22024127 | 0.91 | HTR2A (0.33) | HTR2A | |
| SCHEMBL25733300 | 0.90 | GNAO1 (0.35) | CCR2CCR1CCR5CXCR4GNAI3 | |
| SCHEMBL21191575 | 0.84 | GNAO1 (0.36) | CCR2CCR1CCR5CXCR4GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | HTR2A 1183/4885CCR2 3929/4885CCR1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.